HeartSciences (HSCS) Cash from Financing Activities (2022 - 2026)
HeartSciences' (HSCS) quarterly Cash from Financing Activities came in at -$63673.0 in Q2 2026, down 163.66% YoY from $100028.0 in Q2 2025, and down 104.22% on a QoQ basis from $1.5 million in Q4 2025.
HeartSciences (HSCS) Cash from Financing Activities (2022 - 2026) Analysis & Trends
HeartSciences (HSCS) has 5 years of Cash from Financing Activities data on file, last reported at -$63673.0 in Q2 2026.
- Quarterly Cash from Financing Activities fell 163.66% year-over-year to -$63673.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $5.2 million (up 89.99% YoY) and the FY2026 annual result came in at $8.0 million, up 193.74% from the prior year.
- Cash from Financing Activities fell to -$63673.0 in Q2 2026, from $1.5 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $9.1 million in Q1 2024 to a low of -$121522.0 in Q1 2023.
- A 5-year average of $1.6 million and a median of $551683.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities jumped 7610.17% — and 2026, when it slumped 163.66%.
- Tracing HSCS's Cash from Financing Activities over 5 years: stood at -$116392.0 in 2022, then surged by 542.15% to $514629.0 in 2023, then surged by 269.53% to $1.9 million in 2024, then fell by 20.66% to $1.5 million in 2025, then tumbled by 104.22% to -$63673.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$63673.0 (Q2 2026), $1.5 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.95 Bn | 193.35 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 128.10 Bn | 124.63 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.91 Bn | 109.69 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.43 Bn | 72.89 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.52 Bn | 32.58 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.94 Bn | 31.83 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn | -213.50 Mn |
| 10 | HeartSciences | 6.51 Mn | 4.81 Mn | - | -63,673.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -63,673.00 |
| Apr 30, 2026 | -63,673.00 |
| Oct 31, 2025 | 1.51 Mn |
| Oct 31, 2025 | 1.51 Mn |
| Jul 31, 2025 | 3.65 Mn |
| Jul 31, 2025 | 3.65 Mn |
| Apr 30, 2025 | 100,028.00 |
| Apr 30, 2025 | 100,028.00 |
| Jan 31, 2025 | 180,187.00 |
| Jan 31, 2025 | 180,187.00 |
| Oct 31, 2024 | 1.90 Mn |
| Oct 31, 2024 | 1.90 Mn |
| Jul 31, 2024 | 551,683.00 |
| Jul 31, 2024 | 551,683.00 |
| Apr 30, 2024 | 377,142.00 |
| Apr 30, 2024 | 377,142.00 |
| Jan 31, 2024 | 9.13 Mn |
| Jan 31, 2024 | 9.13 Mn |
| Oct 31, 2023 | 514,629.00 |
| Oct 31, 2023 | 514,629.00 |